Engineered patients' T cells to target human papillomavirus positive cancer cells
2015
National Cancer Institute, Bethesda, USA
The human papillomavirus (HPV) E6 and E7 oncoproteins are constitutively expressed by HPV+ cancers and they are absent from healthy tissues, making them ideal targets for immunotherapy using T cells. However, poor results of early clinical trials have shown that HPV+ tumor cells possess diverse means of immune evasion. In the present study, the researchers have genetically engineered tumor-infiltrating T cells from an HPV+ cancer patient to express an oncoprotein-specific TCR and tested for specific reactivity against HPV+ epithelial tumor cells. Engineered cells showed great affinity specifically to HPV+ cells and a capacity to kill them. The study demonstrates that HPV+ tumours can be targeted by E6 specific T cell receptor gene engineered T cells, and they provide the foundation for a novel cellular
therapy directed against HPV+ malignancies.
Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6
Christian S. Hinrichs
Added on: 09-14-2021
[1] https://clincancerres.aacrjournals.org/content/21/19/4431[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
